Importantly, SGLT2 inhibition has recently been found to reduce heart failure events to a similar extend in patients with and without diabetes demonstrating broad therapeutic efficacy of the drug class in HFrEF [7, 8]. This evidence concerns the gene SLC5A2 and heart failure.